ESBATECH
Founded in 1998 as a spin out of the University of Zurich, ESBATech is committed to becoming one of the leading developers of fully human antibody fragments for therapeutic applications. The company applies its proprietary, fully human single-chain antibody frameworks to generate product candidates against targets of clinical relevance. ESBATech is focused on delivering high concentrations of its therapeutic antibody fragments to the targeted sites, in combination with extremely low systemic load, in order to achieve low risk of systemic drug reactions using topical and local delivery.
ESBATECH
Social Links:
Industry:
Biotechnology Health Care Therapeutics
Founded:
1998-01-01
Address:
Schlieren, Zurich, Switzerland
Country:
Switzerland
Website Url:
http://www.esbatech.com
Total Employee:
51+
Status:
Active
Contact:
+41447334990
Email Addresses:
[email protected]
Total Funding:
72 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible LetsEncrypt Content Delivery Network Amazon Gravatar Profiles OpenResty AdBlock Acceptable Ads Bodis DNS
Similar Organizations
Amrit Advanced Biotech
Amrit Advanced Biotech is a startup involved in genetics, telomeres health applications, and cancer mitigation.
Chimeron Bio
Chimeron Bio develops agents for personalized cancer gene therapy.
PDC Biotech
PDC Biotech develops novel compounds and therapeutics for the treatment of preterm labor and primary dysmenorrhea.
Current Advisors List
Current Employees Featured
Founder
Investors List
VI Partners
VI Partners investment in Series B - ESBATech
SV Health Investors
SV Health Investors investment in Series B - ESBATech
Novartis Venture Fund
Novartis Venture Fund investment in Series B - ESBATech
HBM Healthcare Investments AG
HBM Healthcare Investments AG investment in Series B - ESBATech
Clarus Ventures
Clarus Ventures investment in Series B - ESBATech
BioMedPartners
BioMedPartners investment in Series B - ESBATech
SV Health Investors
SV Health Investors investment in Series B - ESBATech
VI Partners
VI Partners investment in Series B - ESBATech
Novartis Venture Fund
Novartis Venture Fund investment in Series B - ESBATech
BioMedPartners
BioMedPartners investment in Series B - ESBATech
Official Site Inspections
http://www.esbatech.com
- Host name: 199.59.243.228
- IP address: 199.59.243.228
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "ESBATech"
ESBATech Company Profile 2024: Valuation, Investors
ESBATech was founded in 1998. Who is the founder of ESBATech? Dominik Escher Ph.D is the founder of ESBATech. Where is ESBATech headquartered? ESBATech is headquartered in Schlieren, Switzerland. What industry is โฆSee details»
ESBATech, a Novartis company Information - RocketReach
ESBATech is a Zurich, Switzerland based company of Novartis and part of the Ophthalmology Disease Area research team of the Novartis Institutes for BioMedical Research (NIBR). โฆSee details»
ESBATech - Products, Competitors, Financials, Employees, โฆ
ESBATech primarily serves the pharmaceutical industry with a focus on addressing sight-threatening eye diseases. It was founded in 1998 and is based in Zurich, Switzerland. In โฆSee details»
Organization | ESBATech AG
ESBATech AG Report issue. For profit Phase 2. Founded: Schlieren Switzerland ... Organization Overview. First Clinical Trial. 2008 NCT00671619. First Marketed Drug. None First NDA โฆSee details»
ESBATech - Swiss Who's Who
In 2009, ESBATech was acquired by Alcon, the world leader in ophthalmology. Since Alcon only acquired the ophthalmic rights of ESBATech, a demerger at the time of acquisition was โฆSee details»
ESBATech, a Novartis company - LinkedIn
ESBATech, a Novartis company | 825 followers on LinkedIn. ESBATech is a Zurich, Switzerland based company of Novartis and part of the Ophthalmology Disease Area research team of the โฆSee details»
ESBATech - VentureRadar
In Spring 2006 it was decided to create two different tailored enterprises, one focused on antibody fragments (ESBATech) and one on small molecules (Oncalis). Oncalis has acquired from the โฆSee details»
ESBATech - Swiss Biotech
ESBATech, now a Novartis company, is recognized for its pioneering role in developing single-chain antibody fragments for ophthalmic indications. The most advanced product from the โฆSee details»
ESBATech, a Novartis Co. GmbH - Drug pipelines, Patents, Clinical ...
Explore ESBATech, a Novartis Co. GmbH with its drug pipeline, therapeutic area, technology platform, 4 clinical trials, 3 news, Drug:DLX-105, ESBA-903.See details»
ESBATech - Crunchbase
ESBATech develops fully human antibody fragments for therapeutic applications, applying the single-chain antibody framework.See details»
ESBATech - Funding, Financials, Valuation & Investors - Crunchbase
ESBATech develops fully human antibody fragments for therapeutic applications, applying the single-chain antibody framework. Search Crunchbase. ... How much funding has this โฆSee details»
ESBATech | EquityNet
Founded in 1998 as a spin out of the University of Zurich, ESBATech is committed to becoming one of the leading developers of fully human antibody fragments for therapeutic applications. โฆSee details»
www.esbatech.com
Www.esbatech.comSee details»
Swiss Biotech Success Stories award winner 2021 ESBATech
1988, this makes ESBATechโs breakthrough all the more impressive and critically important. Some 11 years after its founding, ESBATech sold its ophthalmic business for USD 589M to โฆSee details»
ESBATech AG | myScience / research / โฆ
ESBATech AG focuses on medical applied research using yeast as model organism. The company has developed several new and powerful platform technologies. These technologies โฆSee details»
ESBATech, a Novartis company Management Team | Org Chart
ESBATech, a Novartis company employs 15 employees. The ESBATech, a Novartis company management team includes Gina Mias (Head of Finance), Peter Lichtlen (Medical Director), โฆSee details»
ESBATech - Contacts, Employees, Board Members, Advisors
ESBATech develops fully human antibody fragments for therapeutic applications, applying the single-chain antibody framework.See details»
Dominik Escher - CEO & Co- Founder @ ESBATech - Crunchbase
Dominik is a founding partner of Pureos and a co-founder and Executive Chairman of CDR-Life. He is also president of the Swiss Biotech Association. Previously, he was a founder and CEO โฆSee details»
ESBATech, a Novartis Co. GmbH (ESBATech, a Novartis Co. GmbH)
ไบ่งฃESBATech, a Novartis Co. GmbH (ESBATech, a Novartis Co. GmbH)ๅ ฌๅธ็่ฏ็ฉ็ฎก็บฟ๏ผๆฒป็้ขๅ๏ผๆๆฏๅนณๅฐ๏ผไปฅๅๅฎ็4้กนไธดๅบ่ฏ้ช, 3็ฏๆฐ้ป๏ผ่ฏ็ฉ:DLX-105๏ผESBA-903ใSee details»